BNR vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe fundamental deterioration. Despite a strong gross margin of 73.02% and a healthy current ratio of 3.15, persistent unprofitability (negative ROE, ROA, and profit margin) and deeply negative earnings surprises over the past 12 quarters undermine any value proposition. The stock's recent 1Y price surge of +414.2% appears disconnected from fundamentals, especially given the lack of analyst coverage, no meaningful dividend, and deteriorating earnings trajectory. While the low debt/equity ratio is favorable, the absence of an Altman Z-Score and deeply negative Forward P/E (-60.47) signal high distress risk and speculative valuation.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BNR vs JNJ: Head-to-Head Comparison
This page compares Burning Rock Biotech Limited (BNR) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.